Advertisement


Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel

2024 ASCO Annual Meeting

Advertisement

Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So most ovarian cancers will become treatment resistant, in particular platinum resistant. We identified AXL receptor tyrosine kinase that's actually expressed in these platinum-resistant ovarian cancers. A targeted therapy was developed named batiraxcept or AVB-500, which actually is a fusion protein that targets GAS6's ligand. So instead of the GAS6 ligand binding to the membrane AXL receptor, this batiraxcept will bind to that GAS6 ligand so that receptor on the tumor will never be activated. So a phase three trial that we presented talked about GOG-3059 or ENGOT OV-66, AXLerate-OC. This really was focusing on the question, if we give our patients who have platinum-resistant ovarian cancer weekly paclitaxel, which is the standard of care, compared to weekly paclitaxel with batiraxcept, would they actually improve in terms of progression-free survival as a primary endpoint and overall survival as a secondary? We also did perform exploratory endpoints looking at the expression of our tumors for AXL as well as GAS6 and then other exploratory blood markers like serum [inaudible 00:01:15] and GAS6 ratio. Our findings did show that there was similar progression-free survival between those patients who received the standard of care weekly paclitaxel compared to those with batiraxcept with weekly paclitaxel in both progression-free survival and overall survival, about 5 months for PFS and 14 months for OS. When we actually did the exploratory analysis looking at the AXL-high tumors, we did see a difference for those patients who actually had high AXL in their tumor, which is about 80% intensity. They actually benefited from the receiving batiraxcept and paclitaxel compared to paclitaxel alone. We saw this both in progression-free survival and overall survival. So this really leads us to ask the next questions in terms of, can we actually develop perhaps this biomarker for AXL? Can we actually target this biomarker and use this biomarker targeted therapy in the future by using this batiraxcept or another AXL inhibitor in combination with paclitaxel for our patients with platinum-resistant ovarian cancer? So in the future, we would like to see if those patients with high-AXL tumors could actually benefit from an AXL inhibitor in platinum-resistant ovarian cancer and really utilize this AXL expression to help focus in on the patients who actually might not benefit from standard of care and may actually benefit from a combination with the AXL inhibitor.

Related Videos

Lymphoma

David J. Andorsky, MD, on DLBCL and FL: New Data on Use of Subcutaneous Epcoritamab

David J. Andorsky, MD, of the Sarah Cannon Research Institute and Rocky Mountain Cancer Centers, discusses EPCORE NHL-6, an ongoing study of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). As outpatients, the study participants were given subcutaneous epcoritamab-bysp to see whether they could be safely monitored and cytokine-release syndrome appropriately managed in the outpatient setting (Abstract 7029).

Leukemia

Yucai Wang, MD, PhD, on Richter Transformation of CLL: Findings on Combination Therapy With an Immune Checkpoint Inhibitor

Yucai Wang, MD, PhD, of the Mayo Clinic, discusses the increased efficacy of combination therapy with pembrolizumab plus a BCR kinase inhibitor compared with pembrolizumab alone in patients with Richter transformation of chronic lymphocytic leukemia (CLL; Abstract 7050).

Prostate Cancer
Genomics/Genetics

Alicia Morgans, MD, MPH, and Susan Halabi, PhD, on Prostate Cancer: New Findings on Classifying Patients Into Risk Groups

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).

Multiple Myeloma

Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse

Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.

Multiple Myeloma

Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib

Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lenalidomide, and dexamethasone deepened responses and increased the rate of measurable residual disease negativity vs isatuximab with lenalidomide and dexamethasone in patients with newly diagnosed transplant-ineligible multiple myeloma (Abstract 7501).

Advertisement

Advertisement




Advertisement